Myotonic dystrophy
Not recruitingSafety and effectiveness study of DYNE-101 in patients with Myotonic Dystrophy Type 1 (DM1)
Safety and effectiveness study of DYNE-101 in patients with Myotonic Dystrophy Type 1 (DM1)
- Disease:Myotonic dystrophy
- Substances:Humanised Igg1 Kappa Fragment Antibody Targeting Tfr1 Conjugated To P125 Oligonucleotide
France- Participants:18–64 years
- Substances:Humanised Igg1 Kappa Fragment Antibody Targeting Tfr1 Conjugated To P125 Oligonucleotide
- Sponsor:Dyne Therapeutics Inc.













